-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $35

Benzinga·10/13/2025 12:12:27
Listen to the news
Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $35.